% alzhub.org library filter
% Source: https://alzhub.org/research?institution=I2802060973&design=trial
% 11 entries, in the order the page lists them. Built from alzhub.org's own records.
% 0 entries have no readable author in the source record and carry no author field.

@article{salloway2014-24450891,
  author  = {Salloway, S. and Sperling, R. and Fox, N. C. and Blennow, K. and Klunk, W. and Raskind, M. and Sabbagh, M. and Honig, L. S. and others},
  title   = {{Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease}},
  journal = {The New England journal of medicine},
  year    = {2014},
  doi     = {10.1056/nejmoa1304839},
  pmid    = {24450891},
  url     = {https://doi.org/10.1056/nejmoa1304839}
}

@article{zimmer2025-40063015,
  author  = {Zimmer, J. A. and Ardayfio, P. and Wang, H. and Khanna, R. and Evans, C. D. and Lu, M. and Sparks, J. and Andersen, S. and Lauzon, S. and Nery, E. S. M. and others},
  title   = {{Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials}},
  journal = {JAMA Neurology},
  year    = {2025},
  doi     = {10.1001/jamaneurol.2025.0065},
  pmid    = {40063015},
  url     = {https://doi.org/10.1001/jamaneurol.2025.0065}
}

@article{bateman2023-37966285,
  author  = {Bateman, R. J. and Smith, J. and Donohue, M. C. and Delmar, P. and Abbas, R. and Salloway, S. and Wojtowicz, J. and Blennow, K. and others},
  title   = {{Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease}},
  journal = {The New England journal of medicine},
  year    = {2023},
  doi     = {10.1056/nejmoa2304430},
  pmid    = {37966285},
  url     = {https://doi.org/10.1056/nejmoa2304430}
}

@article{mintun2021-33720637,
  author  = {Mintun, M. A. and Lo, A. C. and Duggan Evans, C. and Wessels, A. M. and Ardayfio, P. A. and Andersen, S. W. and Shcherbinin, S. and Sparks, J. and others},
  title   = {{Donanemab in Early Alzheimer's Disease}},
  journal = {The New England journal of medicine},
  year    = {2021},
  doi     = {10.1056/nejmoa2100708},
  pmid    = {33720637},
  url     = {https://doi.org/10.1056/nejmoa2100708}
}

@article{wang2025-40172303,
  author  = {Wang, H. and Serap Monkul Nery, E. and Ardayfio, P. and Khanna, R. and Otero Svaldi, D. and Gueorguieva, I. and Shcherbinin, S. and Andersen, S. W. and Hauck, P. M. and Engle, S. E. and others},
  title   = {{Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction}},
  journal = {Alzheimer's \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz.70062},
  pmid    = {40172303},
  url     = {https://doi.org/10.1002/alz.70062}
}

@article{salloway2009-19923550,
  author  = {Salloway, S. and Sperling, R. and Gilman, S. and Fox, N. C. and Blennow, K. and Raskind, M. and Sabbagh, M. and Honig, L. S. and others},
  title   = {{A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease}},
  journal = {Neurology},
  year    = {2009},
  doi     = {10.1212/wnl.0b013e3181c67808},
  pmid    = {19923550},
  url     = {https://doi.org/10.1212/wnl.0b013e3181c67808}
}

@article{sims2023-37459141,
  author  = {Sims, JR. and Zimmer, J. A. and Evans, C. D. and Lu, M. and Ardayfio, P. and Sparks, J. and Wessels, A. M. and Shcherbinin, S. and others},
  title   = {{Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial}},
  journal = {JAMA},
  year    = {2023},
  doi     = {10.1001/jama.2023.13239},
  pmid    = {37459141},
  url     = {https://doi.org/10.1001/jama.2023.13239}
}

@article{curtis2015-25622185,
  author  = {Curtis, C. and Gamez, J. E. and Singh, U. and Sadowsky, C. H. and Villena, T. and Sabbagh, M. N. and Beach, T. G. and Duara, R. and others},
  title   = {{Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density}},
  journal = {JAMA neurology},
  year    = {2015},
  doi     = {10.1001/jamaneurol.2014.4144},
  pmid    = {25622185},
  url     = {https://doi.org/10.1001/jamaneurol.2014.4144}
}

@article{salloway2011-21917766,
  author  = {Salloway, S. and Sperling, R. and Keren, R. and Porsteinsson, A. P. and van Dyck, C. H. and Tariot, P. N. and Gilman, S. and Arnold, D. and others},
  title   = {{A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease}},
  journal = {Neurology},
  year    = {2011},
  doi     = {10.1212/wnl.0b013e3182309fa5},
  pmid    = {21917766},
  url     = {https://doi.org/10.1212/wnl.0b013e3182309fa5}
}

@article{liu2015-26208959,
  author  = {Liu, E. and Schmidt, M. E. and Margolin, R. and Sperling, R. and Koeppe, R. and Mason, N. S. and Klunk, W. E. and Mathis, C. A. and others},
  title   = {{Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials}},
  journal = {Neurology},
  year    = {2015},
  doi     = {10.1212/wnl.0000000000001877},
  pmid    = {26208959},
  url     = {https://doi.org/10.1212/wnl.0000000000001877}
}

@article{sperling2012-22305802,
  author  = {Sperling, R. and Salloway, S. and Brooks, D. J. and Tampieri, D. and Barakos, J. and Fox, N. C. and Raskind, M. and Sabbagh, M. and others},
  title   = {{Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis}},
  journal = {The Lancet. Neurology},
  year    = {2012},
  doi     = {10.1016/s1474-4422(12)70015-7},
  pmid    = {22305802},
  url     = {https://doi.org/10.1016/s1474-4422(12)70015-7}
}